These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

609 related items for PubMed ID: 15792914

  • 1. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J.
    Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
    [Abstract] [Full Text] [Related]

  • 2. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 3. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK.
    Cancer; 2004 Feb 15; 100(4):859-68. PubMed ID: 14770445
    [Abstract] [Full Text] [Related]

  • 4. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan 15; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 5. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 Jan 15; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 6. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr 15; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 7. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P.
    Am J Nephrol; 2006 Apr 15; 26(2):149-56. PubMed ID: 16636531
    [Abstract] [Full Text] [Related]

  • 8. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun 15; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 9. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T, German Aranesp Study Group.
    Nephrol Dial Transplant; 2004 May 15; 19(5):1224-30. PubMed ID: 14993489
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
    Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A.
    Oncologist; 2007 Jun 15; 12(6):727-37. PubMed ID: 17602062
    [Abstract] [Full Text] [Related]

  • 11. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
    Glaspy JA, Tchekmedyian NS.
    Oncology (Williston Park); 2002 Oct 15; 16(10 Suppl 11):23-9. PubMed ID: 12435170
    [Abstract] [Full Text] [Related]

  • 12. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.
    Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire WP.
    J Support Oncol; 2003 Oct 15; 1(2):131-8. PubMed ID: 15352656
    [Abstract] [Full Text] [Related]

  • 13. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.
    Oncology (Williston Park); 2002 Oct 15; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC.
    Nefrologia; 2004 Oct 15; 24(1):54-9. PubMed ID: 15083958
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun 15; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 16. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.
    Stevenson JG, Natale JJ.
    Pharmacotherapy; 2007 Mar 15; 27(3):434-46. PubMed ID: 17316154
    [Abstract] [Full Text] [Related]

  • 17. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S, Boulton H, Gokal R.
    J Nephrol; 2004 Mar 15; 17(5):687-92. PubMed ID: 15593036
    [Abstract] [Full Text] [Related]

  • 18. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M, Hannedouche T, Fitte H, Cayotte JL, Urena P, Réglier JC, Groupe de l'étude NESP 20000117.
    Nephrol Ther; 2006 Sep 15; 2(4):191-9. PubMed ID: 16966064
    [Abstract] [Full Text] [Related]

  • 19. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul 15; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 20. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
    Glaspy J.
    Oncology (Williston Park); 2006 Jul 15; 20(8 Suppl 6):29-32. PubMed ID: 16925109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.